Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

Investigations of the Effects of Aprovel, Lipanor and Their Combination Onto the Endothelial Functions of Dyslipidemic Patients Measure by Laser Doppler Flow-Metry.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00350038

Enrollment

Registered

2006-07-10

Start date

2005-02-28

Completion date

2007-08-31

Last updated

2008-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Dyslipidemia

Brief summary

The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.

Interventions

DRUGIrbesartan

DRUGCiprofibrate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

45 Years to 70 Years

Healthy volunteers

Inclusion criteria

* hypertensive + dyslipidemic + damaged endothelial function

Exclusion criteria

* hepatic and kidney damage, * IDDM (Insulin Dependent Diabetes Mellitus) * Freckson V type hyperlipoproteinaemia The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Design outcomes

Primary

Measure	Time frame
Microvascular reactivity	—

Secondary

Measure	Time frame
Reach of target blood pressure	—
Measurements of safety laboratory parameters	—

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026